Replies to post #103912 on Savvy Trades and Investments

[wadegarret]

RN- GERN

Option premiums is interesting, but I wouldn't buy or sell a stock based on what option players think. Bottom line is, GERN has a drug(Imetelstat) that just finished phase 3 with stellar results in treating two types of blood cancers(low risk MDS and MF). What's excited me is, their drug Imetelstat treats the cancer by healing damaged bone marrow. No other drug treating these cancers heals the bone marrow. All the respondents(40%-60%) in phase 3 have not needed blood transfusions for a year or more now. Also Imetelstat has fast track designation. The company says the target market has $3B revenue potential by 2030. Thing is, if Imetelstat truely does heal the underlying cancer(by healing the bone marrow), the drug would be more like a cure than a band-aid, which is what their competitors have. Either way, all the respondents in phase 3 have not had anemia, and therefore no need for blood transfusions for 12-18 months so far. If you follow cancer drugs, even giving patients an extra 12-18 months of a healthy life is pretty good. The big question is, how long will these respondents be able to stay healthy for, without the bone marrow becoming diseased again. That is the risk, but for now, things look promising.